Medtronic PLC $MDT Stock: Chicago Partners Investment Group LLC Grows Holdings

Key Points

• Chicago Partners Investment Group increased its Medtronic stake by 59.4% in the third quarter, to 31,979 shares valued at about $3.05 million. Institutional investors and hedge funds collectively own 82.06% of the stock.
• Medtronic reported quarterly EPS of $1.45, beating the $1.39 consensus, while revenue of $9.76 billion also exceeded estimates and grew 13.7% year over year. The company set FY 2027 EPS guidance of $5.94–$6.00.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $102.88. Medtronic’s quarterly dividend is $0.72 per share, equivalent to a 2.8% annual yield.

Chicago Partners Investment Group LLC grew its holdings in Medtronic PLC (NYSE:MDT - Free Report) by 59.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,979 shares of the medical technology company's stock after acquiring an additional 11,919 shares during the period. Chicago Partners Investment Group LLC's holdings in Medtronic were worth $3,051,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Activest Wealth Management boosted its stake in shares of Medtronic by 470.9% during the 3rd quarter. Activest Wealth Management now owns 314 shares of the medical technology company's stock worth $27,000 after acquiring an additional 259 shares in the last quarter. IAG Wealth Partners LLC bought a new position in shares of Medtronic in the second quarter valued at approximately $30,000. Team Financial Group LLC bought a new position in shares of Medtronic in the third quarter valued at approximately $31,000. Pin Oak Investment Advisors Inc. acquired a new stake in shares of Medtronic in the second quarter worth $32,000. Finally, Community Bank N.A. bought a new stake in shares of Medtronic during the 2nd quarter worth $33,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Medtronic Price Performance

NYSE MDT traded down $3.02 on Friday, reaching $101.82. The company's stock had a trading volume of 7,451,083 shares, compared to its average volume of 27,950,256. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The firm has a market cap of $130.24 billion, a PE ratio of 25.08, a price-to-earnings-growth ratio of 2.32 and a beta of 0.56. The business has a 50-day moving average price of $92.70 and a 200 day moving average price of $88.45.

Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. Medtronic's revenue was up 13.7% on a year-over-year basis. During the same quarter last year, the company earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Sell-side analysts expect that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were given a dividend of $0.72 per share. The ex-dividend date was Friday, September 25th. This represents a $2.88 annualized dividend and a yield of 2.8%. Medtronic's dividend payout ratio is 70.94%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Stifel Nicolaus raised their target price on shares of Medtronic from $80.00 to $95.00 and gave the company a "hold" rating in a research note on Wednesday, September 2nd. Wells Fargo & Company upped their price target on Medtronic from $102.00 to $104.00 and gave the stock an "overweight" rating in a report on Wednesday, September 2nd. Needham & Company LLC restated a "buy" rating on shares of Medtronic in a research note on Thursday, September 17th. UBS Group reaffirmed a "cautious" rating on shares of Medtronic in a research report on Wednesday, October 14th. Finally, Robert W. Baird increased their price target on shares of Medtronic from $91.00 to $100.00 and gave the company a "neutral" rating in a report on Wednesday, September 2nd. Eighteen investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $102.88.

Insider Activity at Medtronic

In related news, EVP Harry Kiil sold 1,483 shares of the firm's stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the transaction, the executive vice president owned 42,186 shares in the company, valued at $3,950,718.90. This trade represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Marinaro sold 10,420 shares of the business's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $96.00, for a total value of $1,000,320.00. Following the sale, the executive vice president directly owned 105,916 shares of the company's stock, valued at $10,167,936. This represents a 8.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,903 shares of company stock valued at $5,889,203 over the last quarter. Corporate insiders own 0.27% of the company's stock.

About Medtronic

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products.

The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Medtronic is headquartered in Dublin, Ireland, and maintains significant operations in Minnesota, where the company was founded.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.